Replies to post #490662 on NorthWest Biotherapeutics Inc (NWBO)

[FeMike]

Since you are so adamant about that one, please comment on NVCR and give us the reason their TLD on TTF was released months before their journal article which was published in JAMA.

[Hopeforthefuture3]

Bio, you are so totally incorrect on this I am rather amazed. It is one thing to challenge others opinions but in this you are trying to change actual facts, not opinions
On September 21st 2018 amrn closed that Friday at $2.99 per share. They had a pr and conference call that weekend and the pr and call announced great tld. Monday September 24th the stock (after tld announcement) closed at $12.40 for a 4x from previous Friday. On November 10th they had another call, presentation of full data by the principal investigator and nejm paper published - all that same day, the following Monday amrn was about $21
Clearly no embargo against releasing tld more than a month before being published in nejm
Get your facts straight as you are clearly incorrect on this

[biosectinvestor]

Here are the PR’a for AMRN during that period. I don’t see the ones you referenced, I do see the ones I linked to…previously, which were published according to the PR’s, with publication in NEJM, including a link to the relevant article.

https://investor.amarincorp.com/press-releases?9e8308bb_year%5Bvalue%5D=2021&op=Filter&9e8308bb_widget_id=9e8308bb&form_build_id=form-ZY52l9LUON6ytqo-Hx84w7n0xq78YFSGkoJhKCpdBpU&form_id=widget_form_base

I have also said previously, and maybe people do not understand what I was saying. This is an OTC stock. Mainstream media frequently only cover publication, and the scientists and often do not ever mention the company or its stock ticker for OTC penny stocks. You do get coverage in the usual places we already see, and maybe some others, and even foreign press. US press coverage barely mentioned GSK, if at all in relation to coverage of its recent very successful oncology trial. But the key thing that transforms the moment is usually some large release of the data either at a conference or a publication in which the company also PR’s the data, and that circumstance is determined by how those companies choose to do the release. In this case, they are publishing the findings, and the journals have specific embargo policies. You can disagree with their approach and think they should just leave it to them and Adam Feuerstein to figure out what was really released. I think NWBo’s strategy seems a bit more reliable for getting the full picture out.